



ASX ANNOUNCEMENT

28 AUGUST 2017

CANN GROUP COMPLETES FIRST HARVEST PRODUCTION

28 August 2017 – Melbourne-based Cann Group is pleased to report it has completed harvest of its first cultivation cycle of medicinal cannabis at its Southern facility in Victoria.

The production process, which includes the curing and drying of harvested material, has been completed, and approval was received from the Office of Drug Control (ODC) late on Friday 25 August to send samples for full analysis.

The plant material was harvested in the first half of August under Cann Group's cannabis research permits as well as its medicinal cannabis permit.

These permits, received in May 2017, allow for the establishment of breeding plants for propagation purposes; a research program being undertaken with CSIRO to develop unique cannabis extracts; and the supply of plant material for manufacturing into medicinal cannabis products for patient use.

Cann Group is producing medicinal cannabis for subsequent manufacturing into a final product that can be accessed by patients via clinical trials, or through the TGA's Authorised Prescriber or Special Access Scheme.

"We are pleased to have successfully completed this first harvest and production process," said Cann Group CEO Peter Crock.

"While this first harvest is relatively small, it has been important to validate our processes as we build up our capacity, and being the first commercial product to be harvested in Australia, this is a key milestone for both Cann Group and the developing medicinal cannabis industry in Australia."

Propagation continues for the next crop of plants to go into production at the Southern facility.

For further information please contact:

Peter Crock
Cann Group Limited
+61 (0) 3 9095 7088

contact@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420

matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access



to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – Canada's second largest listed medicinal cannabis company – is a cornerstone investor in Cann, with a 19.9% shareholding.